secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARTELO BIOSCIENCES, INC. (ARTL)
CIK:        0001621221
Form:       8-K
Filed at:   2026-02-05T23:59:59+00:00
Accession:  0001640334-26-000221
Event type: regulatory
Sentiment:  negative
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Artelo Biosciences gets Nasdaq panel exception to cure listing deficiencies by March 30
--------------------------------------------------------------------------------

- Panel granted exception to regain compliance with $2.5M stockholders' equity rule by March 30, 2026.
- Company held 2025 annual meeting on Jan 30, curing annual meeting rule deficiency previously cited by Nasdaq.
- Company previously received delist determination in Nov 2025; hearing stayed action.
- Company intends to take all reasonable measures to regain compliance, but no assurance of success.
- Failure to demonstrate compliance by March 30 could result in delisting from Nasdaq.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1621221/000164033426000221/0001640334-26-000221-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1621221/000164033426000221/artl_8k.htm
  HTML page:      https://secwatch.observer/filing/0001640334-26-000221

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer